Tuesday, August 14, 2012

Envivio Inc Slumps On Earnings Guidance (VCLK, NKE, ENVI, PFE)

ValueClick Inc (NASDAQ:VCLK), on August 3, 2012, stock had its “buy” rating reaffirmed by Needham & Company.

The company released its earnings data on August 2. The company reported $0.21 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.22 by $0.01. The company’s revenue was up 28.7% compared to the same quarter last year. Analysts expect that the company will post $1.14 EPS for the current fiscal year.

Get Free Trend Analysis on CHSP

NIKE, Inc (NYSE:NKE) shares gained 0.16% to $96 in the after hour trading after the company announced that its Board of Directors has declared a quarterly cash dividend of $0.36 per share on the company`s outstanding Class A and Class B Common Stock payable on October 1, 2012, to shareholders of record at the close of business on September 4, 2012.

Envivio Inc (NASDAQ:ENVI) stock plunged 43.86% to $3.20 in the after hour trading after the company cut its second quarter revenue outlook, citing a general slowdown in spending by its service provider customers, particularly in North America and Western Europe.

The company now expects second quarter revenue to be in the range of $10 million to $11 million, as compared to its previous guidance of $17 million to $18 million. Analysts expect the company to post revenue of $17.65 million for the second quarter.

Get Daily Earnings Report New Here

Pfizer Inc. (NYSE:PFE) stock gained 0.13% to $23.75 in the after hour trading after the company announced that it has entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium), a prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD). Under the terms of the agreement, Pfizer will acquire the exclusive global rights to market NEXIUM for the approved over-the-counter indications in the United States, Europe and the rest of the world. Under the agreement, Pfizer will make an upfront payment of $250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales.

No comments:

Post a Comment

Privacy Policy | Legal Disclaimer